

REMARKS

The foregoing amendments are presented to place the application in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825 and to correct an obvious typographical error in the specification.

Enclosed herewith is a revised Sequence Listing in both paper and computer readable form as required by 37 C.F.R. § 1.821(c) and (e). Amendments directing its entry into the specification have also been incorporated herein. The content of the paper and computer readable copies are the same and no new matter has been added.

The revised Sequence Listing corrects the errors noted in the Notice to Comply. A copy of the Notice is attached herewith as required. The revised Sequence Listing has been run through the PTO Checker software (version 4.4.0) and no errors were found.

In view of the foregoing, it is believed that each requirement set forth in the Notice has been satisfied, and that the application is now in compliance with the Sequence Rules under 37 C.F.R. § 1.821-1.825.

The specification is amended on page 19 to correct an obvious typographical error. A skilled artisan would understand that the reference to "Table 3" is an error since such table lists amino acid and DNA sequences. A skilled artisan would further understand that this reference should be to Table 4, as the paragraphs on pages 18 and 19 of the specification refer to "wild-type" and "V165F/G300V/H313K" mutants which are listed in column 1 of Table 4. No new matter has been added by this typographical correction.

Attorney Docket No. 2006_1464A
Serial No. 10/591,751
July 11, 2007

Favorable action on the merits is respectfully requested.

Respectfully submitted,

Hirofumi NAKAMURA et al.

By: W. Cheek
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/WRS/mjw/nrj
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
July 11, 2007